ReviewBlood vessels, thrombosis & hemostasis2026
From oversight to insight: the curious case of the endothelial insulin receptor.
Review in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin is produced in the pancreas and regulates blood glucose levels by binding to the insulin receptor (IR) thereby stimulating glucose uptake into cells. Inadequate insulin production or dysregulated IR signaling leads to diabetes. Most research, to date, has focused on enhancing insulin production or correcting impaired IR signaling in tissues of nutrient exchange, for example, muscle or fat. However, the transendothelial trafficking of insulin to target tissues is also crucial in regulating organismal responses to insulin. In fact, this process has been established as the rate-limiting step for glucose disposal. Initially, it was believed that the transendothelial trafficking of insulin was dependent on endothelial IR. Unfortunately, subsequent studies have demonstrated that mice lacking endothelial IR possess minimal changes in insulin sensitivity. These studies have contributed to the widespread belief that endothelial IR does not regulate insulin trafficking and insulin sensitivity. However, recent genetic studies from our laboratory, and others, have shown that enhancing endothelial IR activity improves insulin sensitivity. These studies underscore the crucial role of endothelial IR in regulating insulin trafficking and metabolism. Now that researchers have conclusively demonstrated the presence and function of IR on endothelial cells (ECs) in vivo, it is essential to clarify why this receptor has been so controversial. Additionally, this timely review aims to encourage vascular biology researchers to explore how endothelial IR is regulated and identify new roles for this receptor on ECs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.